» Articles » PMID: 27475769

Neurobiology of Addiction: a Neurocircuitry Analysis

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2016 Aug 1
PMID 27475769
Citations 1345
Authors
Affiliations
Soon will be listed here.
Abstract

Drug addiction represents a dramatic dysregulation of motivational circuits that is caused by a combination of exaggerated incentive salience and habit formation, reward deficits and stress surfeits, and compromised executive function in three stages. The rewarding effects of drugs of abuse, development of incentive salience, and development of drug-seeking habits in the binge/intoxication stage involve changes in dopamine and opioid peptides in the basal ganglia. The increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/negative affect stage involve decreases in the function of the dopamine component of the reward system and recruitment of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of the extended amygdala. The craving and deficits in executive function in the so-called preoccupation/anticipation stage involve the dysregulation of key afferent projections from the prefrontal cortex and insula, including glutamate, to the basal ganglia and extended amygdala. Molecular genetic studies have identified transduction and transcription factors that act in neurocircuitry associated with the development and maintenance of addiction that might mediate initial vulnerability, maintenance, and relapse associated with addiction.

Citing Articles

Opioidergic modulation of monetary incentive delay fMRI responses.

Turton S, Hawkins P, Muller-Pollard C, Zois E, Conrod P, Zelaya F Psychopharmacology (Berl). 2025; .

PMID: 40053107 DOI: 10.1007/s00213-025-06753-7.


Sex differences in the microglial response to stress and chronic alcohol exposure in mice.

Soares A, Garcia-Rivas V, Fai C, Thomas M, Zheng X, Picciotto M Biol Sex Differ. 2025; 16(1):19.

PMID: 40038827 PMC: 11881309. DOI: 10.1186/s13293-025-00701-y.


The psychedelic (-)-2,5-dimethoxy-4-iodoamphetamine [(-)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats.

Salinsky L, Merritt C, Garcia E, Fox R, Zamora J, Anastasio N Psychopharmacology (Berl). 2025; .

PMID: 40035828 DOI: 10.1007/s00213-025-06765-3.


Editorial: Molecular mechanisms in psychiatry 2023: addictive disorders.

Fernandez-Lopez L, Almela P, Falcon M, Navarro-Zaragoza J Front Psychiatry. 2025; 16:1568150.

PMID: 40034183 PMC: 11872940. DOI: 10.3389/fpsyt.2025.1568150.


Involvement of CB1R and CB2R Ligands in Sleep Disorders and Addictive Behaviors in the Last 25 Years.

Perez-Morales M, Espinoza-Abad R, Garcia-Garcia F Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006078 PMC: 11860062. DOI: 10.3390/ph18020266.


References
1.
Uhl G, Grow R . The burden of complex genetics in brain disorders. Arch Gen Psychiatry. 2004; 61(3):223-9. DOI: 10.1001/archpsyc.61.3.223. View

2.
Hawkins J, Catalano R, MILLER J . Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychol Bull. 1992; 112(1):64-105. DOI: 10.1037/0033-2909.112.1.64. View

3.
Schultz W, Dayan P, Montague P . A neural substrate of prediction and reward. Science. 1997; 275(5306):1593-9. DOI: 10.1126/science.275.5306.1593. View

4.
Costa-Mattioli M, Monteggia L . mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci. 2013; 16(11):1537-43. DOI: 10.1038/nn.3546. View

5.
Squeglia L, Tapert S, Sullivan E, Jacobus J, Meloy M, Rohlfing T . Brain development in heavy-drinking adolescents. Am J Psychiatry. 2015; 172(6):531-42. PMC: 4451385. DOI: 10.1176/appi.ajp.2015.14101249. View